

# OUTPATIENT DIALYSIS SERVICES PAYMENT SYSTEM

payment**basics**

Revised:  
October 2022

Individuals with end-stage renal disease (ESRD)—irreversible loss of kidney function—require either dialysis or kidney transplantation to survive. In 1972, the Social Security Act extended all Medicare Part A and Part B benefits to individuals with ESRD who are entitled to receive Social Security benefits. In 2020, there were nearly 384,000 fee-for-service (FFS) Medicare ESRD beneficiaries on dialysis, representing about 1 percent of all FFS Medicare beneficiaries.

Because of the scarcity of kidneys available for transplantation, most patients with ESRD (about 70 percent) receive maintenance dialysis. Medicare spending for outpatient dialysis and injectable drugs administered during dialysis was about \$12.3 billion in 2020 and is a predominant share of revenues for dialysis facilities.

Beginning in 1983, Medicare paid dialysis facilities a predetermined rate (the composite rate) intended to cover a specific bundle of services provided to patients in a given dialysis treatment. To improve provider efficiency, Medicare implemented in 2011 a modernized prospective payment system (PPS) for outpatient dialysis services. The Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) broadened the payment bundle to include dialysis drugs, laboratory tests, and other ESRD-related items and services that were previously separately billable. MIPPA also required CMS to implement a pay-for-performance program beginning in 2012. Table 1 summarizes the key features of the dialysis PPS.

## Defining the care that Medicare buys

Medicare covers two methods of dialysis—hemodialysis and peritoneal dialysis. In hemodialysis, a patient's blood is cycled through a dialysis machine, which filters

out body waste. About 87 percent of all dialysis patients undergo hemodialysis typically three times per week in dialysis facilities. Peritoneal dialysis uses the lining of the peritoneal cavity to filter excess waste products, which are then drained from the abdomen. Patients undergo peritoneal dialysis five to seven times per week in their homes.

The unit of payment is a single dialysis treatment. Although different equipment, supplies, and labor are needed for hemodialysis and peritoneal dialysis, the payment system that began in 2011 does not differentiate payment based on dialysis method for adults. Medicare's payment rate is based on a regimen of three dialysis treatments per week.

Under the dialysis PPS, facilities are paid a single case-mix-adjusted payment which includes composite rate services and ESRD-related drugs, laboratory services, and medical equipment and supplies. The ESRD drugs included under the broader payment bundle include: (1) Part B ESRD-related drugs (including injectable erythropoietin, iron, and vitamin D analogs, and their oral equivalents); and (2) Part D oral ESRD-related drugs with or without an injectable equivalent.<sup>1</sup>

## Setting the payment rates


The base payment for each dialysis treatment is intended to cover all operating and capital costs that efficient providers would incur in furnishing dialysis treatment episodes in dialysis facilities or in patients' homes. For 2022, the base payment rate is \$257.90 for both freestanding facilities and for hospital-based facilities (Figure 1). The base rate is adjusted for differences in labor costs by multiplying the labor-related portion of the base payment amount (52.3 percent) by a version of the hospital wage index.

*The policies discussed in this document were current as of September 30, 2022, and reflect any relevant changes implemented in response to the COVID-19 public health emergency as of that date. This document does not reflect proposed legislation or regulatory actions.*

**MEDPAC**

425 I Street, NW  
Suite 701  
Washington, DC 20001  
ph: 202-220-3700  
www.medpac.gov

**Figure 1 Dialysis prospective payment system in 2022**



Note: TDAPA (transitional drug add-on payment adjustment), TPNIES (transitional add-on payment adjustment for new and innovative equipment and supplies). This figure represents the dialysis prospective payment system for beneficiaries 18 and older. For beneficiaries under 18: (1) the base rate, adjusted for geographic factors, is multiplied by patient case-mix characteristics (age and dialysis method); (2) the low-volume adjustment and rural factors do not apply; and (3) the outlier payment policy and add-on for self-dialysis training do apply. The payment rate may be reduced by up to 2 percent for facilities that do not achieve or make progress toward specified quality measures.

Source: MedPAC analysis of CMS's final rule for the end-stage renal disease prospective payment system for calendar year 2022.

**Patient-level adjustments**—For adults, the wage-adjusted base rate is then adjusted for case mix using the following measures:

- age (18–44, 45–59, 60–69, 70–79, ≥80 years),
- two body measurement variables—body surface area and body mass index,
- specific acute and chronic comorbidities, and
- onset of dialysis (for the first four months a patient receives dialysis).

For children under the age of 18 years, CMS adjusts the base rate by age and dialysis modality.

**Facility-level adjustments**—CMS makes two facility-level adjustments to the base rate. First, CMS adjusts the base rate by 23.9 percent to account for the costs that low-volume facilities incur. A low-volume facility is defined as one that furnishes fewer than 4,000 treatments in each of the three years before the payment year and that has not opened, closed or received a new provider number due to a change in ownership during the three-year period. In addition, CMS considers the proximity to other commonly-owned facilities within five miles of the facility in question. For

**Table 1 Key features of the prospective dialysis payment system**

**Payment method feature**

Payment bundle	<ul style="list-style-type: none"> <li>• Composite rate services (i.e., dialysis services paid for under the former PPS, which include: nursing, dialysis equipment and supplies, social services, and certain laboratory tests and drugs)</li> <li>• Part B injectable dialysis drugs and their oral equivalents</li> <li>• ESRD-related laboratory tests</li> <li>• Selected ESRD Part D drugs</li> <li>• Self-dialysis training services</li> </ul>
Unit of payment	Single dialysis treatment
Self-dialysis training services adjustment	Yes
Beneficiary-level adjustments	<ul style="list-style-type: none"> <li>• For adults: age, dialysis onset, body surface, body mass, specific acute (pericarditis; gastrointestinal tract bleeding or hemorrhage) and chronic (hereditary hemolytic or sickle cell anemias; myelodysplastic syndrome) patient comorbidities</li> <li>• For pediatric patients: age, dialysis method</li> </ul>
Facility-level adjustments	<ul style="list-style-type: none"> <li>• Wage index</li> <li>• Low-volume adjustment</li> <li>• Adjustment for rural location</li> </ul>
Outlier policy	Applies to the portion of the broader payment bundle composed of the drugs and services that were previously separately billable
Transitional add-on payment adjustments for selected new ESRD-related items	Pays facilities an add-on payment for the following qualifying ESRD items: (1) drugs and biologics and (2) equipment and supplies.
Quality incentive program	For 2022, 14 measures.

Note: PPS (prospective payment system), ESRD (end-stage renal disease), FDA (Food and Drug Administration). Payments for pediatric patients are not eligible for the low-volume or rural adjustments.

Source: MedPAC analysis of CMS 2020–2022 final ESRD rules.

payment years 2021 through 2023, CMS holds dialysis facilities harmless if an increase in their 2020 treatment counts is related to COVID and would have prevented them from qualifying for the low-volume payment adjustment in those payment years.

CMS also includes an adjustment (of 0.8 percent applied to the base PPS rate) for all facilities located in rural areas.

**Quality incentive adjustment**—The bundled payment rate is reduced by up to 2 percent for facilities that do not achieve or make progress toward specified quality measures.

**Outlier payments**

CMS pays facilities an outlier payment when a beneficiary’s payment per treatment for outlier services exceeds

a threshold, which is the beneficiary's predicted payment amount per treatment for the outlier services plus a fixed dollar loss amount. Outlier services include drugs, laboratory services, and other items that facilities separately billed under the old payment method. Services that are paid under a transitional add-on payment policy are not eligible for outlier payments. The outlier threshold amount for 2022 is \$118 for adults. Medicare pays 80 percent of the facilities' costs above the threshold.

### **Transitional add-on payments for new technologies**

In 2016, CMS established a drug designation process (as statutorily mandated) for determining when ESRD-related oral-only drugs are no longer oral only and therefore must be paid under the ESRD PPS instead of under Part D. Under the process, once the Food and Drug Administration (FDA) approves an equivalent injectable product (or other non-oral forms), CMS pays facilities for both the oral and non-oral products under a transitional drug add-on payment adjustment (TDAPA) until sufficient claims data (at least two years' worth) for rate-setting analysis are available; thereafter, all forms of the product will be included in the PPS bundle.

Because an injectable equivalent of the oral calcimimetic was approved by the FDA in 2017, between 2018 and 2020, injectable and oral calcimimetics qualified for the TDAPA under the ESRD PPS. Beginning in 2021, CMS included both the injectable and oral calcimimetics into the PPS bundle and accounted for the calcimimetics' cost by adding \$9.93 to the PPS base rate.

Other qualifying ESRD-related drugs and biologics that the FDA approves on or after January 1, 2020, are eligible for a transitional add-on payment as well:

- \* Medicare pays a TDAPA for certain new products (e.g., that are not generics) that treat a condition included in one of 11 ESRD functional categories of products

that are covered under the PPS. After the two-year TDAPA period ends, CMS includes the drug in the PPS bundle, without any change to the ESRD PPS base rate.

- \* Medicare pays a TDAPA for new ESRD products that treat a condition for which there is no ESRD-related functional category for at least two years. Once sufficient claims-based utilization data are available, CMS includes the drug in the PPS bundle, and the base rate is modified, as appropriate, to account for the new product in the bundle.

Under the TDAPA policy, Medicare pays facilities 100 percent of each product's Part B average sales price (ASP).

In addition, as of 2020, there is an add-on payment—the “transitional add-on payment adjustment for new and innovative equipment and supplies” (TPNIES)—for ESRD-related equipment and supplies that meet certain criteria, including newness and substantial clinical improvement. Equipment and supplies that are considered a capital asset are not eligible for TPNIES, with the exception of home dialysis machines when used for a single patient in the home. For a two-year period, Medicare pays 65 percent of a qualifying technology's cost using information from invoices and other relevant sources. Thereafter, the piece of equipment or supply is included in the PPS payment bundle, without any change to the ESRD PPS base rate.

Currently, one new ESRD drug (Korsuva) is paid under the TDAPA policy (for new drugs in an existing ESRD functional category) since April 2022. One home hemodialysis machine has qualified under the TPNIES policy since January 2022.

### **Self-dialysis training add-on payment**

In 2022, the dialysis training add-on payment is \$95.60 per treatment. CMS pays up to 15 training sessions for peritoneal dialysis and 25 sessions for hemodialysis.

### **Payment updates**

Medicare payments to dialysis facilities are updated annually by the ESRD market basket, which measures the price increases of goods and services facilities buy to produce patient care, reduced by a productivity adjustment. ■

- 1 Currently, phosphate binders are the only drugs that fall into this category; however, statutory and regulatory provisions have delayed their inclusion into the payment bundle until 2025.